scholarly journals Hand foot syndrome associated with docetaxel treatment in metastatic prostate cancer: A case report

2017 ◽  
Vol 50 (3) ◽  
pp. 280-282
Author(s):  
Erdem Şen ◽  
İrem Öner ◽  
Özlem Ata
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Metastatic Prostate Cancer ◽  
Docetaxel Treatment ◽  
Hand Foot Syndrome

scholarly journals Hepatic failure induced by cyproterone acetate: A case report and literature review

2014 ◽  
Vol 8 (5-6) ◽  
pp. 458 ◽  
Author(s):  
Jae Heon Kim ◽  
Byung Wook Yoo ◽  
Won Jae Yang
Keyword(s):  
Prostate Cancer ◽  
Critical Care ◽  
Case Report ◽  
Literature Review ◽  
Hepatic Failure ◽  
Cyproterone Acetate ◽  
Metastatic Prostate Cancer ◽  
Gross Hematuria

Cyproterone acetate (CPA) is an anti-androgenic drug that has been used to manage prostate cancer. The drug is well-tolerated, but has hepatotoxic effects. Hepatic failure induced by CPA is rare and urologists tend to overlook its severity. We report a patient with metastatic prostate cancer who developed CPA-induced hepatic failure that manifested as bilirubinuria, which was initially misinterpreted as gross hematuria. The patient died despite receiving critical care. The aim of this study is to sound the alarm about CPA-induced hepatic failure.

scholarly journals Eruptive nodules of the head and neck: a case report of metastatic prostate cancer

2014 ◽  
Vol 20 (2) ◽  
Author(s):  
Gabrielle Brown ◽  
Drew Kurtzman ◽  
Fangru Lian ◽  
James Sligh
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Head And Neck ◽  
Metastatic Prostate Cancer

scholarly journals Multimodal therapy in the treatment of metastatic prostate cancer: A case report

2018 ◽  
Vol 21 ◽  
pp. 92-94
Author(s):  
Olamide O. Omidele ◽  
Howard I. Schiff ◽  
William Oh ◽  
Ashutosh Tewari
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Metastatic Prostate Cancer ◽  
Multimodal Therapy

scholarly journals Hidden intra-mandibular carcinoma cuniculatum appearing in a patient with metastatic prostate cancer: a case report

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Elyette Broly ◽  
Philippe Barthélémy ◽  
Saïd Ciftci ◽  
Christian Borel ◽  
Martin Broly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Metastatic Prostate Cancer ◽  
Carcinoma Cuniculatum

Isolated Pleural Involvement in Recurrent Metastatic Prostate Cancer: A Case Report

CHEST Journal ◽  
2014 ◽  
Vol 145 (3) ◽  
pp. 308A
Author(s):  
Abhay Vakil ◽  
Hineshkumar Upadhyay ◽  
Khalid Sherani ◽  
Kelly Cervellione ◽  
Mohammed Babury
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Metastatic Prostate Cancer ◽  
Pleural Involvement

Apatinib in combination with hypofractionation radiotherapy in bone metastatic prostate cancer: Results from a pilot, multicenter study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16523-e16523
Author(s):  
Ming Zeng ◽  
Feng Zhao ◽  
Wei Tian
Keyword(s):  
Prostate Cancer ◽  
Dose Escalation ◽  
Pain Control ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Growth Factor Receptor ◽  
Radiographic Evaluation ◽  
Large Sample Size ◽  
Dose Escalation Study ◽  
Hand Foot Syndrome

e16523 Background: To study safety and efficacy of apatinib, a vascular endothelial growth factor receptor-2 (VEGF2) inhibitor, in combination with radiotherapy in patients with bone metastatic prostate cancer (BMPC), based on potential synergistic antitumor activities of apatinib and Radiation Therapy (RT). Methods: In a dose escalation study, 18 patients (6/cohort) received apatinib at 250 mg every other day, 250 mg or 500 mg daily. The 250 mg daily cohort was expanded to 19 patients in combination with RT (6 Gy/fraction, 5 fraction in total), comparing with the RT alone cohort with 10 patients. Evaluations included adverse events (AEs), prostate specific antigen (PSA) levels, radiographic evaluation and pain relief. Results: In the dose escalation patients, common apatinib-related AEs (arAEs) were fatigue (11, 61%), anorexia 10, 55%), hand foot syndrome (9, 50%), proteinuria (8, 44%), and HTN (8, 44%). Grade 3 arAEs included HTN, proteinuria, and liver dysfunction. No treatment-related death occurred. In the apatinib plus RT cohort, AEs were increased comparing to either apatinib alone or RT alone; The combination cohort showed improvement in pain control. Conclusions: In BMPC patients, apatinib at less than 500 mg daily dose as mono-therapy had tolerable toxicity, consistent with previous reports in patients with other tumors. Apatinib at dose of 250mg daily combining with RT improved pain control while the overall AEs were manageable. Further studies are needed in large sample size trials. Clinical trial information: NCT02998242.

Sign in / Sign up

Export Citation Format

Share Document